• PD 173074: Structural Basis of Angiogenesis Inhibition

  2026-10-06

  The 1998 EMBO Journal study combined receptor-kinase pharmacology, mouse angiogenesis models, and 2.5 Å X-ray crystallography to explain how PD 173074 binds FGFR1. Its central contribution was linking inhibition of FGF- and VEGF-driven angiogenesis to direct structural complementarity within the FGFR1 ATP-binding pocket, while leaving clinical translation and broader selectivity questions unresolved.

• Telatinib in Angiogenesis and TNBC Research

  2026-10-06

  Telatinib, also known as BAY 57-9352, is a multitarget kinase research compound linked to VEGFR signaling, c-Kit, and PDGFR pathways. This overview compares supplier-reported target information with a 2026 in vitro study of lapatinib plus Telatinib in a triple-negative breast cancer model, emphasizing evidence strength, interpretation limits, and translational boundaries.

• KPT-330: Interpreting XPO1 Inhibition

  2026-10-05

  KPT-330, also known as Selinexor, is examined through an evidence-first lens that connects CRM1 biology with subtype-specific DLBCL findings. This analysis clarifies what the 2026 platinum-sensitization study demonstrates, what remains uncertain, and how the evidence informs cancer research.

• FAK Inhibitor 14 in Ovarian Cancer Research

  2026-10-05

  A source-grounded overview of FAK signaling in cholesterol-adapted ovarian cancer models, with emphasis on the PARP1–FAK/Src–COL5A1 axis, the evidentiary role of FAK Inhibitor 14, and the limits of translating preclinical findings into therapeutic conclusions.

• GI 254023X: Interpreting ADAM10 Evidence

  2026-10-04

  GI 254023X is a selective ADAM10 inhibitor for studying sheddase biology, Notch1 signaling, and endothelial barrier protection. This article presents an evidence-centered framework that connects its reported findings with lessons from BACE inhibition research without overstating translational relevance.

• Anlotinib Hydrochloride: Evidence Beyond VEGFR2

  2026-10-03

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose anti-angiogenic profile is best understood through converging biochemical, endothelial, ex vivo, and in vivo evidence. This article examines what the data establish, where interpretation remains limited, and how the compound can inform cancer research without overstating translational conclusions.

• ARCA Cy5 EGFP mRNA (5-moUTP) Workflow Guide

  2026-10-02

  ARCA Cy5 EGFP mRNA (5-moUTP) separates delivery from translation with a covalent Cy5 tracking signal and EGFP output. Use it to compare carriers, optimize mRNA transfection in mammalian cells, and troubleshoot uptake, localization, endosomal escape, and expression in one workflow.

• Hyaluronic Acid Sodium Salt for ECM and siRNA Studies

  2026-10-01

  Hyaluronic acid sodium salt connects extracellular matrix modeling with high-molecular-weight biomaterial and siRNA nanoparticle workflows. This guide translates a preclinical Pseudomonas aeruginosa lung-injury study into practical formulation, assay, and troubleshooting decisions while emphasizing solubility and batch-validation controls.

• Dantrolene Sodium Salt: Calcium Research Workflows

  2026-10-01

  Dantrolene sodium salt provides a mechanism-focused way to probe ryanodine receptor activity, intracellular calcium release, and calmodulin-dependent signaling. This practical guide connects calcium imaging, pancreatitis and neurodegeneration models, and carefully controlled exploratory CRISPR assays without overstating evidence across domains.

• Trelagliptin succinate: Assay Workflow Guide

  2026-09-30

  This scenario-driven guide explains how Trelagliptin succinate (SKU A3889) can support reproducible cell viability, proliferation, cytotoxicity, and metabolic studies. It combines formulation guidance, model-specific concentration ranges, and analytical quality-control considerations with links to primary evidence.

• Anlotinib hydrochloride Assay Workflows

  2026-09-30

  Build integrated angiogenesis experiments around Anlotinib hydrochloride, combining endothelial migration, capillary tube formation, viability, and receptor-phosphorylation readouts. The workflow distinguishes direct pathway inhibition from nonspecific toxicity while translating a clinically relevant case report into practical cancer research assay choices.

• Mitoxantrone: A Transporter-Aware Framework

  2026-09-29

  Mitoxantrone research is more informative when cytotoxicity is interpreted alongside intracellular exposure and ABCG2-mediated efflux. This article develops a mechanistic framework for oncology and antiviral assays while connecting product handling to the 2024 marein–ABCG2 study.

• Anlotinib Inhibits Angiogenesis via Three Kinases

  2026-09-29

  The reference study shows that anlotinib suppresses angiogenesis by jointly inhibiting VEGFR2, PDGFRβ, and FGFR1, with downstream attenuation of ERK signaling. Its combination of endothelial migration, tube formation, ex vivo vessel sprouting, and CAM assays provides a useful mechanistic framework for evaluating multi-target anti-angiogenic compounds.

• Dual SMAD/Wnt Inhibition for iPSC-RGC Differentiation

  2026-09-28

  Chavali and colleagues developed a chemically defined differentiation strategy that combines dual SMAD and canonical Wnt inhibition to generate retinal ganglion cells (RGCs) from induced pluripotent stem cells (iPSCs) with improved yield and reproducibility. The approach produced RGC-enriched populations without genetic modification and incorporated Thy-1-based magnetic purification, providing a practical platform for glaucoma modeling and regenerative-ophthalmology research.

• Temafloxacin Pharmacokinetics: Evidence and Implications

  2026-09-28

  This 1991 review integrates oral and intravenous temafloxacin data to explain its high bioavailability, prolonged elimination half-life, tissue distribution, and predominantly renal excretion. Its main contribution is a practical pharmacokinetic framework for interpreting dosing intervals and renal-function effects, while its findings remain specific to temafloxacin and the clinical evidence available at the time.

7461 records 1/498 page Next 12345 下5页 Last page